Maximize your product valuation and deal structuring skills to gain the competitive advantage when negotiating a deal
Pre-event to BIO-Europe Spring®
Course Overview
This intensive and in-depth course in product valuation and deal structuring will provide you with definitive advantages during future negotiations.
Over two days you will examine best practices for assessing and valuing assets with interactive case studies and group discussion.
You will gain an insight into both the buy and sell perspective and how each arrives at their negotiating positions.
Armed with the skills acquired in this course, you will have the confidence to calculate and negotiate the financial aspects of transactions involving the divestiture, transfer and acquisition of biopharm technology rights.
What will you learn?
Valuation concepts
Valuation concepts
Examine valuation concepts and understand why valuations differ between similar technologies
Valuation methods
Valuation methods
Review valuation methods, techniques and factors to ensure you are estimating both risk and return adequately
Impact on negotiation
Impact on negotiation
Examine why valuations of the same asset may differ impacting on negotiations
Appreciate both sides
Appreciate both sides
Participate in group case studies from the point of view of the “buy-side” and the “sell-side” to gain an appreciation of challenges both parties encounter
Forecast revenue
Forecast revenue
Learn to forecast revenue using both patient and market data to accurately value an asset in preparation for negotiations
Evaluate Risk
Evaluate Risk
获得实际技能评估risk ensuring you are prepared for real life negotiations
Who is this course for?
This is an intensive valuation course intended for the following professionals:
- Business development and licensing
- Intellectual property personnel involved in the licensing process
- Alliance management professionals
- Biotech company CEOs
- R&D personnel who have significant interaction with business development
- Professionals who are new to business development and licensing or who have limited deal experience
Direct valuation experience is not required; however, it will be helpful if participants have a general understanding of biotech and/or pharmaceutical product development phases, industry terminology, financial terminology, and exposure to using Microsoft Excel spreadsheets. Valuation experts will leave this class with new insights, sharper skills and the opportunity to have had in-depth discussions with other experts in the field.
Obtain the best possible deal in future negotiations.
This course will review valuation methods and help you to forecast revenue in order to accurately value an asset in preparation for your negotiations. With in-depth case studies and group discussions, you will gain a practical insight into both the buy and sell perspective, granting you the confidence to negotiate the financial aspects of transactions.